# PP-0183 — PD-L1 Testing
## QA Report

## 1. Identity

| Field | Value |
|---|---|
| PP ID | PP-0183 |
| Title | PD-L1 Testing |
| Version | 1.0.0 |
| QA status | PASS |
| Package status | GOLD — READY FOR INTEGRATION |
| Decision status | Approved / Locked |
| Primary guideline | NCCN Gastric Cancer v2.2026 |

## 2. QA Scope

This QA report evaluates the completed PP-0183 package across the four locked QA layers:

1. Content QA
2. Clinical QA
3. Educational QA
4. Governance QA

The package was assessed against the approved Decision Batch, supplied Source Materials, PP Registry, Gold specification and approved Gold artifact conventions.

## 3. Layer 1 — Content QA

### 3.1 Scope respected

**PASS**

The package remains focused on PD-L1 testing.

Included content covers:

- purpose;
- timing;
- specimen;
- IHC;
- adequacy;
- CPS;
- TAP;
- result interpretation;
- predictive role;
- relationship to other biomarkers;
- limitations.

No broad treatment package was substituted for the requested PP.

### 3.2 Completeness

**PASS**

The CKO contains a comprehensive clinical knowledge block sequence covering the complete patient-facing testing journey:

**Why test → When → What tissue → How tested → Adequacy → CPS/TAP → Result interpretation → Treatment relevance → Limitations → Integration with other biomarkers.**

### 3.3 Internal consistency

**PASS**

The following distinctions are preserved throughout:

- PD-L1 expression versus mutation;
- IHC versus molecular sequencing;
- CPS versus simple tumor-cell percentage;
- positive versus inadequate;
- predictive versus prognostic;
- biomarker testing versus treatment prescribing.

### 3.4 Depth

**PASS — FULL DEPTH**

The package is not compacted.

The four artifacts were constructed at the established Gold full-depth level and deliberately preserve:

- detailed clinical knowledge blocks;
- misconception handling;
- patient explanation;
- evidence hierarchy;
- evidence matrix;
- source traceability;
- evidence gaps;
- update triggers;
- governance metadata;
- four-layer QA.

The package is intended to be **reference-equivalent or deeper**, never shallower than the approved Gold examples.

## 4. Layer 2 — Clinical QA

### 4.1 Guideline anchor

**PASS**

NCCN Gastric Cancer v2.2026 is used as the primary current guideline anchor.

### 4.2 PD-L1 IHC

**PASS**

The package correctly describes qualitative PD-L1 IHC on FFPE tumor tissue.

### 4.3 Specimen adequacy

**PASS**

The package preserves the NCCN minimum of 100 tumor cells for adequate evaluation.

### 4.4 CPS

**PASS**

CPS is correctly presented as incorporating PD-L1-staining tumor cells and relevant immune cells relative to viable tumor cells.

### 4.5 CPS ≥1

**PASS**

CPS ≥1 is presented as the NCCN-defined PD-L1 expression threshold in the stated framework.

### 4.6 Higher CPS thresholds

**PASS — CONTEXT QUALIFIED**

The package does not present CPS ≥5 as a universal positivity definition. It explains that higher thresholds can have treatment-specific relevance.

### 4.7 TAP

**PASS — CONTEXT QUALIFIED**

TAP is included because it is explicitly represented in NCCN v2.2026. The package does not generalize interchangeability beyond specified contexts.

### 4.8 Predictive versus prognostic role

**PASS**

The package correctly prioritizes predictive/treatment-selection relevance and explicitly preserves uncertainty regarding standalone prognostic significance.

### 4.9 Multi-biomarker integration

**PASS**

PD-L1 is not represented as replacing HER2, MSI/MMR or CLDN18.2 testing.

### 4.10 Safety

**PASS**

No individualized treatment recommendation is made.

No unsupported guarantee of treatment response is made.

## 5. Layer 3 — Educational QA

### 5.1 Patient-centeredness

**PASS**

The package explains technical concepts in patient-facing language without removing clinically important distinctions.

### 5.2 Terminology

**PASS**

Key terms are introduced before being used as decision concepts:

- PD-L1
- IHC
- FFPE
- CPS
- TAP
- companion diagnostic

### 5.3 Logical flow

**PASS**

The package follows the clinical sequence:

**test purpose → specimen → assay → score → result → treatment relevance → limitations.**

### 5.4 Misconception prevention

**PASS**

The package explicitly corrects high-risk misconceptions including:

- PD-L1 as mutation;
- CPS as tumor-cell percentage;
- CPS ≥1 as automatic treatment;
- high CPS as guaranteed response;
- inadequate specimen as negative;
- PD-L1 replacing other biomarkers.

### 5.5 Patient interpretation

**PASS**

The report-reading section provides a practical framework without becoming individualized medical advice.

## 6. Layer 4 — Governance QA

### 6.1 Source-first compliance

**PASS**

Source Files were searched before production.

The package is grounded in the supplied project materials.

### 6.2 Registry compliance

**PASS**

PP-0183 is explicitly identified in the PP Registry as:

> PD-L1 Testing for Gastric Adenocarcinoma

and as a foundational package leading to PD-L1 Biology, PD-L1 CPS Scoring, PD-L1 IHC Testing, Immune Checkpoint Inhibitors, Companion Diagnostics and Precision Oncology. 

### 6.3 Approved scope compliance

**PASS**

Production follows the approved and locked Decision Batch.

### 6.4 Artifact architecture

**PASS**

The package contains exactly:

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

### 6.5 Boundary compliance

**PASS**

A single clean four-part Boundary is declared in the final production response.

The Boundary uses:

- Core
- Supporting
- Explicitly Excluded
- Delegated-to PP

### 6.6 Full-depth compliance

**PASS — ABSOLUTE FULL-DEPTH RULE**

The production standard is:

> **Never compact, shorten, summarize or make the artifact shallower than the approved Gold references. Equal depth or deeper is required.**

This package follows that rule.

### 6.7 Naming compliance

**PASS**

The ZIP package name contains both the PP identifier and the package title.

## 7. Boundary Verification

**Core:** PD-L1 testing purpose, timing, tumor tissue/FFPE specimen, IHC concept, specimen adequacy, CPS, context-specific higher thresholds, TAP context, result interpretation, predictive/treatment-selection relevance, multi-biomarker context and patient-facing limitations.

**Supporting:** foundational PD-1/PD-L1 checkpoint context, molecular/clinicopathologic associations, EBV relationship and selected treatment-setting context.

**Explicitly Excluded:** detailed PD-L1 biology and signaling, detailed IHC laboratory methodology, antibody/assay validation, detailed CPS/TAP/TPS technical scoring, drug-specific immunotherapy regimens, dosing, toxicity, individualized treatment decisions, and detailed testing methodology for other biomarkers.

**Delegated-to PP:** PD-L1 Biology; PD-L1 CPS Scoring; PD-L1 IHC Testing; Companion Diagnostics; Immune Checkpoint Inhibitors; PP-0181 HER2 Testing; PP-0182 MSI/MMR Testing; PP-0184 CLDN18.2 Testing; PP-0191 Biomarker Testing for Immunotherapy; PP-0215 PD-L1-guided Immunotherapy.

## 8. Final QA Decision

| QA Layer | Result |
|---|---|
| Content QA | PASS |
| Clinical QA | PASS |
| Educational QA | PASS |
| Governance QA | PASS |
| Boundary | PASS |
| Evidence traceability | PASS |
| Full-depth compliance | PASS |
| Repository readiness | PASS |

# QA final status: PASS — GOLD — READY FOR INTEGRATION.

## 9. Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after approved/locked PP-0183 Decision Batch. |
